Design and analysis of a Petri Net model of the Von Hippel-Lindau (VHL) tumor suppressor interaction network

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Minervini, Giovanni ^a   Panizzoni, Elisabetta ^a   Giollo, Manuel ^a   Masiero, Alessandro ^a   Ferrari, Carlo ^a   Tosatto, Silvio C E ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VON HIPPEL LINDAU PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; HUMAN; METABOLISM; PETRI NET MODEL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; RELIABILITY; VON HIPPEL LINDAU DISEASE; ALGORITHM; BIOLOGICAL MODEL; CLUSTER ANALYSIS; GENE INACTIVATION; GENETIC TRANSCRIPTION; GENETICS; PROTEIN PROTEIN INTERACTION;

ALGORITHMS; CLUSTER ANALYSIS; COMPUTER SIMULATION; GENE KNOCKOUT TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MODELS, BIOLOGICAL; PROTEIN INTERACTION MAPS; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84902324935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096986     Document Type: Article

References (53)

1. Soga T (2013) Cancer metabolism: Key players in metabolic reprogramming. Cancer Sci 104: 275-281.
2. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
3. Thomas JG, Olson JM, Tapscott SJ, Zhao LP (2001) An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles. Genome Res 11: 1227-1236. doi:10.1101/gr.165101. (Pubitemid 32677297)
4. Leonardi E, Murgia A, Tosatto SCE (2009) Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network. FEBS Lett 583: 3704-3710.
5. Leonardi E, Martella M, Tosatto SCE, Murgia A (2011) Identification and in silico analysis of novel von Hippel-Lindau (VHL) gene variants from a large population. Ann Hum Genet 75: 483-496.
6. Minervini G, Masiero A, Moro S, Tosatto SCE (2013) In silico investigation of PHD-3 specific HIF1-α proline 567 hydroxylation: A new player in the VHL/HIF-1α interaction pathway? FEBS Lett. 587(18): 2996-3001.
7. Wu M, Liu L, Hijazi H, Chan C (2013) A multi-layer inference approach to reconstruct condition-specific genes and their regulation. Bioinforma Oxf Engl: 1-12. doi:10.1093/bioinformatics/btt186.
8. Almaas E (2007) Biological impacts and context of network theory. J Exp Biol 210: 1548-1558.
9. Weitz JS, Benfey PN, Wingreen NS (2007) Evolution, interactions, and biological networks. PLoS Biol 5: e11. doi:10.1371/journal.pbio.0050011.
10. Proulx SR, Promislow DEL, Phillips PC (2005) Network thinking in ecology and evolution. Trends Ecol Evol 20: 345-353. (Pubitemid 40772082)
11. Mahon PC, Hirota K, Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 2675-2686. (Pubitemid 32988878)
12. Heiner M, Sriram K (2010) Structural analysis to determine the core of hypoxia response network. PloS One 5: e8600. doi:10.1371/journal.pone.0008600.
13. Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, et al. (2004) Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. Mol Biol Cell 15: 3042-3052. (Pubitemid 38850102)
14. Yu Y, Wang G, Simha R, Peng W, Turano F, et al. (2007) Pathway switching explains the sharp response characteristic of hypoxia response network. PLoS Comput Biol 3: e171. doi:10.1371/journal.pcbi.0030171.
15. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12: 417-423. (Pubitemid 28512618)
16. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90. (Pubitemid 24232386)
17. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320. (Pubitemid 23231974)
18. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol Off J Am Soc Clin Oncol 22: 4991-5004. (Pubitemid 46646218)
19. Vortmeyer AO, Huang SC, Pack SD, Koch CA, Lubensky IA, et al. (2002) Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene. 14; 21(8): 1167-70.
20. Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
21. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, et al. (1997) Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 94: 9102-9107.
22. Frew IJ, Krek W (2008) pVHL: a multipurpose adaptor protein. Sci Signal 1: pe30. doi:10.1126/scisignal.124pe30.
23. Schoenfeld AR, Davidowitz EJ, Burk RD (2000) Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. Proc Natl Acad Sci U S A 97: 8507-8512. (Pubitemid 30639703)
24. Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578.
25. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, et al. (2012) The IntAct molecular interaction database in 2012. Nucleic Acids Res 40: D841-846.
26. Frew IJ, Krek W (2007) Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 19: 685-690. (Pubitemid 350216423)
27. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, et al. (2009) VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11: 994-1001.
28. Tang N, Mack F, Haase V (2006) pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell 26. doi:10.1128/MCB.26.7.2519.
29. Sackmann A, Heiner M, Koch I (2006) Application of Petri net based analysis techniques to signal transduction pathways. BMC Bioinformatics 7: 482.
30. Chaouiya C (2007) Petri net modelling of biological networks. Brief Bioinform 8: 210-219.
31. Grunwald S, Speer A, Ackermann J, Koch I (2008) Petri net modelling of gene regulation of the Duchenne muscular dystrophy. Biosystems 92: 189-205.
32. Rohr C, Marwan W, Heiner M (2010) Snoopy - a unifying Petri net framework to investigate biomolecular networks. Bioinforma Oxf Engl 26: 974-975.
33. Maynard MA, Evans AJ, Hosomi T, Hara S, Jewett MAS, et al. (2005) Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J Off Publ Fed Am Soc Exp Biol 19: 1396-1406. (Pubitemid 41278998)
34. Li QF, Wang XR, Yang YW, Lin H (2006) Hypoxia upregulates hypoxia inducible factor (HIF)-3alpha expression in lung epithelial cells: characterization and comparison with HIF-1alpha. Cell Res 16: 548-558.
35. Smith TG, Robbins PA, Ratcliffe PJ (2008) The human side of hypoxia-inducible factor. Br J Haematol 141: 325-334. (Pubitemid 351521147)
36. Richardson SM, Knowles R, Tyler J, Mobasheri A, Hoyland JA (2008) Expression of glucose transporters GLUT-1, GLUT-3, GLUT-9 and HIF-1alpha in normal and degenerate human intervertebral disc. Histochem Cell Biol 129: 503-511.
37. Vannucci SJ, Maher F, Simpson IA (1997) Glucose transporter proteins in brain: Delivery of glucose to neurons and glia. Glia 21: 2-21. (Pubitemid 27389636)
38. Takeda J, Kayano T, Fukomoto H, Bell GI (1993) Organization of the human GLUT2 (pancreatic beta-cell and hepatocyte) glucose transporter gene. Diabetes 42: 773-777. (Pubitemid 23127169)
39. Heather LC, Pates KM, Atherton HJ, Cole MA, Ball DR, et al. (2013) Differential Translocation of FAT/CD36 and GLUT4 Coordinates Changes in Cardiac Substrate Metabolism During Ischemia and Reperfusion. Circ Heart Fail. doi:10.1161/CIRCHEARTFAILURE.112.000342.
40. Kim J, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
41. Kim BY, Kim H, Cho EJ, Youn HD (2008) Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation. Exp Mol Med 40: 71-83. (Pubitemid 351346819)
42. Choi J-W, Park SC, Kang GH, Liu JO, Youn H-D (2004) Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Cancer Res 64: 35-39. (Pubitemid 38114079)
43. Roe J-S, Youn H-D (2006) The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle Georget Tex 5: 2054-2056. (Pubitemid 44553737)
44. Fels DR, Koumenis C (2005) HIF-1alpha and p53: the ODD couple? Trends Biochem Sci 30: 426-429.
45. Berndt JD, Moon RT, Major MB (2009) Beta-catenin gets jaded and von Hippel-Lindau is to blame. Trends Biochem Sci 34: 101-104.
46. Hergovich A, Lisztwan J, Thoma CR, Wirbelauer C, Barry RE, et al. (2006) Priming-Dependent Phosphorylation and Regulation of the Tumor Suppressor pVHL by Glycogen Synthase Kinase 3. Mol Cell Biol 26: 5784-5796. (Pubitemid 44134334)
47. Heiner M, Koch I, Will J (2004) Model validation of biological pathways using Petri nets-demonstrated for apoptosis. Biosystems 75: 15-28. (Pubitemid 38887549)
48. Bortfeldt RH, Schuster S, Koch I (2011) Exhaustive analysis of the modular structure of the spliceosomal assembly network: a petri net approach. Stud Health Technol Inform 162: 244-278.
49. Heiner M (2009) Understanding Network Behavior by Structured Representations of Transition Invariants. Algorithmic Bioprocesses. Natural Computing Series. Springer Berlin Heidelberg. 367-389. Available: http://link.springer.com/chapter/10.1007/978-3-540-88869-7-19.
50. Zhu JL, Kaytor EN, Pao CI, Meng XP, Phillips LS (2000) Involvement of Sp1 in the transcriptional regulation of the rat insulin-like growth factor-1 gene. Mol Cell Endocrinol 164: 205-218. (Pubitemid 30665514)
51. Okabe T, Nawata H (1998) [Functional role of nur77 family in T-cell apoptosis and stress response]. Nihon Rinsho Jpn J Clin Med 56: 1734-1738.
52. Murphy EP, Conneely OM (1997) Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. Mol Endocrinol Baltim Md 11: 39-47. (Pubitemid 27021252)
53. Tabernero J (2007) The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents. Mol Cancer Res 5: 203-220.